OncoCyte Net Profit Margin 2014-2025 | IMDX
OncoCyte net profit margin from 2014 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.
| OncoCyte Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2025-03-31 |
$0.00B |
$-0.06B |
-1966.67% |
| 2024-12-31 |
$0.00B |
$-0.06B |
-6100.00% |
| 2024-09-30 |
$0.00B |
$-0.04B |
0.00% |
| 2024-06-30 |
$0.00B |
$-0.04B |
0.00% |
| 2024-03-31 |
$0.00B |
$-0.04B |
0.00% |
| 2023-12-31 |
$0.00B |
$-0.03B |
0.00% |
| 2023-09-30 |
$0.00B |
$-0.06B |
0.00% |
| 2023-06-30 |
$0.00B |
$-0.06B |
0.00% |
| 2023-03-31 |
$0.00B |
$-0.06B |
0.00% |
| 2022-12-31 |
$0.00B |
$-0.07B |
0.00% |
| 2022-09-30 |
$0.00B |
$-0.06B |
3200.00% |
| 2022-06-30 |
$0.00B |
$-0.07B |
6800.00% |
| 2022-03-31 |
$0.00B |
$-0.07B |
-7000.00% |
| 2021-12-31 |
$0.00B |
$-0.06B |
-3200.00% |
| 2021-09-30 |
$0.01B |
$-0.03B |
-680.00% |
| 2021-06-30 |
$0.01B |
$-0.03B |
-540.00% |
| 2021-03-31 |
$0.00B |
$-0.03B |
-866.67% |
| 2020-12-31 |
$0.00B |
$-0.03B |
-1500.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Services |
$0.090B |
$0.002B |
|
OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California.
|
